[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://www.allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it provides clinical-stage product, such as LLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors ; Claudin 18.2 for the treatment of gastric and pancreatic cancer; FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 75, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 649097, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 994595, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 47, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 260500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 45, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 747390, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 59, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin M. Beneski", "age": 47, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 61, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 58, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 40, "title": "SVP & Corporate Controller", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.4, "open": 1.4, "dayLow": 1.375, "dayHigh": 1.48, "regularMarketPreviousClose": 1.4, "regularMarketOpen": 1.4, "regularMarketDayLow": 1.375, "regularMarketDayHigh": 1.48, "payoutRatio": 0.0, "beta": 0.987, "forwardPE": -1.0431656, "volume": 2039412, "regularMarketVolume": 2039412, "averageVolume": 5390501, "averageVolume10days": 2926130, "averageDailyVolume10Day": 2926130, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 315034240, "fiftyTwoWeekLow": 1.23, "fiftyTwoWeekHigh": 3.78, "priceToSalesTrailing12Months": 14319.738, "fiftyDayAverage": 1.7382, "twoHundredDayAverage": 2.2882, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 113313872, "profitMargins": 0.0, "floatShares": 156267663, "sharesOutstanding": 217264992, "sharesShort": 34756318, "sharesShortPriorMonth": 39095990, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.16, "heldPercentInsiders": 0.17661, "heldPercentInstitutions": 0.77796, "shortRatio": 9.82, "shortPercentOfFloat": 0.2218, "impliedSharesOutstanding": 220303008, "bookValue": 1.989, "priceToBook": 0.72900957, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -257590000, "trailingEps": -1.32, "forwardEps": -1.39, "enterpriseToRevenue": 5150.63, "enterpriseToEbitda": -0.465, "52WeekChange": -0.5735294, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 1.45, "targetHighPrice": 14.0, "targetLowPrice": 3.0, "targetMeanPrice": 9.18182, "targetMedianPrice": 9.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 292476000, "totalCashPerShare": 1.346, "ebitda": -243843008, "totalDebt": 90756000, "quickRatio": 8.287, "currentRatio": 8.541, "totalRevenue": 22000, "debtToEquity": 21.497, "revenuePerShare": 0.0, "returnOnAssets": -0.27011, "returnOnEquity": -0.55134, "grossProfits": -192276992, "freeCashflow": -99133376, "operatingCashflow": -200300000, "revenueGrowth": -1.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -11703.728, "financialCurrency": "USD", "symbol": "ALLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "averageDailyVolume3Month": 5390501, "fiftyTwoWeekLowChange": 0.22000003, "fiftyTwoWeekLowChangePercent": 0.17886181, "fiftyTwoWeekRange": "1.23 - 3.78", "fiftyTwoWeekHighChange": -2.33, "fiftyTwoWeekHighChangePercent": -0.6164021, "fiftyTwoWeekChangePercent": -57.352943, "earningsTimestamp": 1741896120, "earningsTimestampStart": 1747047540, "earningsTimestampEnd": 1747396800, "earningsCallTimestampStart": 1741899600, "earningsCallTimestampEnd": 1741899600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.32, "epsForward": -1.39, "epsCurrentYear": -1.19976, "priceEpsCurrentYear": -1.2085751, "fiftyDayAverageChange": -0.2881999, "fiftyDayAverageChangePercent": -0.16580366, "twoHundredDayAverageChange": -0.83819985, "twoHundredDayAverageChangePercent": -0.36631408, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "postMarketTime": 1744932456, "regularMarketTime": 1744920001, "firstTradeDateMilliseconds": 1539264600000, "postMarketChangePercent": 1.96551, "postMarketPrice": 1.4785, "postMarketChange": 0.0285, "regularMarketChange": 0.05000007, "regularMarketDayRange": "1.375 - 1.48", "fullExchangeName": "NasdaqGS", "cryptoTradeable": false, "longName": "Allogene Therapeutics, Inc.", "exchange": "NMS", "messageBoardId": "finmb_558022022", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketChangePercent": 3.5714335, "regularMarketPrice": 1.45, "shortName": "Allogene Therapeutics, Inc.", "marketState": "CLOSED", "displayName": "Allogene Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]